Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of avelumab in relapsed or refractory stage III/IV extranodal natural killer/T-cell lymphoma
KCT0003206Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in extranodal natural killer/T-cell lymphoma (ENKTL), sponsored by Merck & Co.. Started Jan 2018; status: recruiting.
02
Drugs
avelumab
03
Conditions
extranodal natural killer/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on KCT0003206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003206.